Clinical trial
Combination Chemotherapy With or Without High Dose Cyclophosphamide and…
NCT00002556 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002556 |
|---|---|
| Title | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma |
| Official title | The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Biological, Drug, Other |
| Interventions | vincristine sulfate, carmustine, melphalan, cyclophosphamide, prednisone, recombinant interferon alfa-2b, laboratory biomarker analysis |
| Enrollment | 312 |
| Start date | Jul 1, 1994 |
| Primary completion | Jan 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | May 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: